INTRODUCTION: Published data addressing the effectiveness of darunavir-ritonavir (DRV/r)-based therapy for multiexperienced patients in developing countries are scarce. This study evaluated the 48-week virologic and immunologic effectiveness of salvage therapy based on DRV/r for the treatment of multidrug-experienced HIV-1-infected adults in Brazil. MATERIALS AND METHODS: A multicenter retrospective cohort study was carried out with multidrug-experienced adults who were on a failing antiretroviral therapy and started a DRV/r-based salvage therapy between 2008 and 2010. The primary effectiveness end point was the proportion of patients with virologic success (plasma HIV-1 RNA <50 copies/mL at week 48). RESULTS: At 48 weeks, 73% of the patients had HIV-RNA <50 copies/mL and a mean increase of 108 CD4 cells/mm(3). Higher baseline viral load, lower baseline CD4 count, younger age, and 3 or more DRV/r-associated resistance mutations were significantly predictive of virologic failure. Concomitant use of raltegravir was strongly associated with virologic success. CONCLUSION: The use of DRV/r-based regimens for salvage therapy is an effective strategy in the clinical care setting of a developing country.
INTRODUCTION: Published data addressing the effectiveness of darunavir-ritonavir (DRV/r)-based therapy for multiexperienced patients in developing countries are scarce. This study evaluated the 48-week virologic and immunologic effectiveness of salvage therapy based on DRV/r for the treatment of multidrug-experienced HIV-1-infected adults in Brazil. MATERIALS AND METHODS: A multicenter retrospective cohort study was carried out with multidrug-experienced adults who were on a failing antiretroviral therapy and started a DRV/r-based salvage therapy between 2008 and 2010. The primary effectiveness end point was the proportion of patients with virologic success (plasma HIV-1 RNA <50 copies/mL at week 48). RESULTS: At 48 weeks, 73% of the patients had HIV-RNA <50 copies/mL and a mean increase of 108 CD4 cells/mm(3). Higher baseline viral load, lower baseline CD4 count, younger age, and 3 or more DRV/r-associated resistance mutations were significantly predictive of virologic failure. Concomitant use of raltegravir was strongly associated with virologic success. CONCLUSION: The use of DRV/r-based regimens for salvage therapy is an effective strategy in the clinical care setting of a developing country.
Authors: Graeme Meintjes; Liezl Dunn; Marla Coetsee; Michael Hislop; Rory Leisegang; Leon Regensberg; Gary Maartens Journal: AIDS Res Ther Date: 2015-12-01 Impact factor: 2.250
Authors: José Antonio Mata-Marín; Gloria Huerta-García; Juan Carlos Domínguez-Hermosillo; Marcelino Chavez-García; Marco Isaac Banda-Lara; Nohemí Nuñez-Rodríguez; Javier Enrique Cruz-Herrera; Jorge Luis Sandoval-Ramírez; Ivan Martínez-Abarca; Alfredo Francisco Villagómez-Ruíz; Bulmaro Manjarrez-Tellez; Jesús Gaytán-Martínez Journal: AIDS Res Ther Date: 2015-09-24 Impact factor: 2.250
Authors: José E Vidal; Ariane M R Dos Santos; Érique J F Peixoto de Miranda; Aluísio C Segurado Journal: Braz J Infect Dis Date: 2017-09-29 Impact factor: 3.257